JP2003504052A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003504052A5 JP2003504052A5 JP2001509486A JP2001509486A JP2003504052A5 JP 2003504052 A5 JP2003504052 A5 JP 2003504052A5 JP 2001509486 A JP2001509486 A JP 2001509486A JP 2001509486 A JP2001509486 A JP 2001509486A JP 2003504052 A5 JP2003504052 A5 JP 2003504052A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/351,778 US7589069B1 (en) | 1999-07-12 | 1999-07-12 | Replication-competent anti-cancer vectors |
| US09/351,778 | 1999-07-12 | ||
| PCT/US2000/018971 WO2001004282A2 (en) | 1999-07-12 | 2000-07-12 | Replication-competent anti-cancer vectors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003504052A JP2003504052A (ja) | 2003-02-04 |
| JP2003504052A5 true JP2003504052A5 (US06573293-20030603-C00009.png) | 2005-12-22 |
| JP4361708B2 JP4361708B2 (ja) | 2009-11-11 |
Family
ID=23382352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001509486A Expired - Fee Related JP4361708B2 (ja) | 1999-07-12 | 2000-07-12 | 複製−コンピテント抗癌ベクター |
Country Status (9)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7589069B1 (en) * | 1999-07-12 | 2009-09-15 | Saint Louis University | Replication-competent anti-cancer vectors |
| CA2439185A1 (en) | 2001-02-23 | 2002-09-06 | Novartis Ag | Vector constructs |
| US8163892B2 (en) * | 2002-07-08 | 2012-04-24 | Oncolys Biopharma, Inc. | Oncolytic virus replicating selectively in tumor cells |
| WO2004087930A1 (en) * | 2003-03-28 | 2004-10-14 | Saint Louis University | Adenovirus replication-competent vectors expressing trail |
| US7815902B2 (en) | 2003-07-09 | 2010-10-19 | Henry Ford Health System | Methods and compositions for cancer therapy using a novel adenovirus |
| WO2005007109A2 (en) * | 2003-07-09 | 2005-01-27 | Henry Ford Health System | Methods and compositions for cancer therapy using a novel adenovirus |
| WO2005049094A1 (en) * | 2003-11-13 | 2005-06-02 | Advantagene, Inc. | A mixed complementary viral vector for gene therapy |
| WO2008136213A1 (ja) * | 2007-04-27 | 2008-11-13 | Oncolys Biopharma Inc. | 放射線増感増強剤 |
| US8696544B2 (en) | 2009-02-05 | 2014-04-15 | Coloplast A/S | Minimally invasive adjustable support |
| WO2011146885A2 (en) * | 2010-05-21 | 2011-11-24 | Virxsys Corporation | Compositions and methods for lentiviral expression of apoa-1 or variants thereof using spliceosome mediated rna trans-splicing |
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| EP4155411A1 (en) | 2016-02-23 | 2023-03-29 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| JP2020510624A (ja) | 2016-12-12 | 2020-04-09 | マルチビア インコーポレイテッド | がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物 |
| US20210094991A1 (en) | 2018-03-19 | 2021-04-01 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| MX2020010499A (es) * | 2018-04-09 | 2020-10-28 | Salk Inst For Biological Studi | Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion. |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US6254862B1 (en) * | 1997-03-03 | 2001-07-03 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
| US6197293B1 (en) * | 1997-03-03 | 2001-03-06 | Calydon, Inc. | Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof |
| US6627190B2 (en) * | 1999-07-12 | 2003-09-30 | Saint Louis University | Recombinant adenovirus vectors that are replication-competent in tert-expressing cells |
| US7589069B1 (en) * | 1999-07-12 | 2009-09-15 | Saint Louis University | Replication-competent anti-cancer vectors |
-
1999
- 1999-07-12 US US09/351,778 patent/US7589069B1/en not_active Expired - Fee Related
-
2000
- 2000-07-12 CA CA2378586A patent/CA2378586C/en not_active Expired - Fee Related
- 2000-07-12 ES ES00975153T patent/ES2231281T3/es not_active Expired - Lifetime
- 2000-07-12 JP JP2001509486A patent/JP4361708B2/ja not_active Expired - Fee Related
- 2000-07-12 AU AU13244/01A patent/AU780613B2/en not_active Ceased
- 2000-07-12 DE DE60017141T patent/DE60017141T2/de not_active Expired - Lifetime
- 2000-07-12 EP EP00975153A patent/EP1196616B1/en not_active Expired - Lifetime
- 2000-07-12 AT AT00975153T patent/ATE286139T1/de not_active IP Right Cessation
- 2000-07-12 WO PCT/US2000/018971 patent/WO2001004282A2/en active IP Right Grant
-
2005
- 2005-10-13 US US11/249,873 patent/US7608255B2/en not_active Expired - Fee Related
-
2009
- 2009-09-16 US US12/561,016 patent/US8658610B2/en not_active Expired - Fee Related
